The state deputy (-SP) defended this Wednesday (28) that the (National Health Surveillance Agency) regulates the use of therapies based on medicinal Cannabis containing a higher level of THC (tetrahydrocannabinol).
In 2023, he is using marijuana oil to treat Parkinson’s. “We need a proportional regulatory framework, suitable for different uses,” said Suplicy during a meeting of the agency’s board of directors that
Today, Anvisa only allows the registration of products with concentrations above 0.2% for the treatment of serious debilitating diseases. “I, as a sufferer of Parkinson’s disease, and most patients on medical advice use medicinal cannabis oil with a significant amount of THC”, stated the parliamentarian.
This Wednesday, the agency is also evaluating rules to approve the cultivation of the plant in Brazil, but with a maximum of 0.3% THC, in cases aimed at manufacturing medicines. Anvisa also evaluates cultivation rules for research and by patient associations, with room for the use of the plant with the highest concentration of the compound.
The new resolutions were presented by Anvisa to comply with the determination of the STJ (Superior Court of Justice) that Union bodies must present a regulation on the . The agency already allowed, in November 2025, that .
During the meeting, Suplicy stated that the STJ has already pointed out that the government can also regulate “other possibilities”, such as Hemp and products with more THC. He also said that the debate on the use of medicinal Cannabis in Brazil “arose from the love and persistence of so many mothers who are present here, who, in search of saving the lives of their sons and daughters, resorted to treatment with an ancestral plant”.
LINK PRESENT: Did you like this text? Subscribers can access seven free accesses from any link per day. Just click the blue F below.
